Search - tctmd.com

Displaying 81 - 100 of 207

Sort: Relevancy | Date

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

News Conference News EAS 2021

For High-Risk Patients Getting Evolocumab in Europe, Other Meds Fall Short

Michael O'Riordan

June 03, 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

News Conference News ACC 2021

Evinacumab Lowers Triglycerides in Severe Hypertriglyceridemia

Yael L. Maxwell

May 16, 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

News Conference News EHRA 2021

RACE 3: Effects Wane for Targeted Therapy in Early AF, HF

April 26, 2021

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

News Conference News AHA 2020

No Doctor? No Problem: Remote, Pharmacist-Led Intervention Cuts CVD Risk

Michael O'Riordan

November 19, 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

News Conference News AHA 2020

Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON

Michael O'Riordan

November 15, 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

News Conference News AHA 2020

OMEMI: Omega-3 Fatty Acids No Help in Elderly MI Patients

November 15, 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

News Conference News AHA 2020

Fish Oil Tanks in STRENGTH, Making Waves for REDUCE-IT

November 15, 2020

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

News Conference News AHA 2020

One Pill to Treat Them All: Polycap Strategy Sees Success in TIPS-3

Michael O'Riordan

November 13, 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

News Conference News AHA 2020

Statin Benefits Confirmed in Elderly, Along With Harmful Effects of High Cholesterol

Michael O'Riordan

November 12, 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

News Conference News TCT 2020

Icosapent Ethyl’s Benefits Consistent in Patients With Prior PCI: REDUCE-IT

October 21, 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

News Conference News TCT 2020

Prophylactic PCI of Vulnerable Plaques? PROSPECT II/ABSORB

Michael O'Riordan

October 14, 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

News Conference News EAS 2020

Just One-Third of European Patients Get to LDL Cholesterol Goals

Michael O'Riordan

October 13, 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

News Conference News EAS 2020

Lp(a) and LPA Genetic Risk Score Both Predict Incident ASCVD: UK Biobank

Michael O'Riordan

October 07, 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

News Conference News ESC 2020

EVAPORATE: Icosapent Ethyl May Slow Atherosclerosis Progression

Yael L. Maxwell

September 02, 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

News Conference News SCAI 2020

Icosapent Ethyl Lowers Revasc Rates Across the Board: REDUCE-IT Data

May 15, 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

News Conference News ACC 2020

Alirocumab Successfully Reduces LDL Cholesterol in Homozygous FH: ODYSSEY HoFH

Yael L. Maxwell

April 06, 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

April 02, 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.